{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T06:58:27Z","timestamp":1760079507673},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2010,8,1]],"date-time":"2010-08-01T00:00:00Z","timestamp":1280620800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clin Transl Oncol"],"published-print":{"date-parts":[[2010,8]]},"DOI":"10.1007\/s12094-010-0555-z","type":"journal-article","created":{"date-parts":[[2010,9,30]],"date-time":"2010-09-30T15:48:00Z","timestamp":1285861680000},"page":"568-573","source":"Crossref","is-referenced-by-count":11,"title":["Serum C-telopeptide levels predict the incidence of skeletal-related events in cancer patients with secondary bone metastases"],"prefix":"10.1007","volume":"12","author":[{"given":"Mar\u00eda Concepci\u00f3n","family":"L\u00f3pez-Carrizosa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pilar Mar\u00eda","family":"Samper-Ots","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aurora Rodr\u00edguez","family":"P\u00e9rez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2010,10,1]]},"reference":[{"key":"555_CR1","doi-asserted-by":"crossref","first-page":"6243s","DOI":"10.1158\/1078-0432.CCR-06-0931","volume":"12","author":"R.E. Coleman","year":"2006","unstructured":"Coleman RE (2006) Clinical features of metastatic bone disease and risk of skeletal morbidity. Clin Cancer Res 12:6243s\u20136249s.","journal-title":"Clin Cancer Res"},{"key":"555_CR2","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1038\/nrc867","volume":"2","author":"G.R. Mundy","year":"2002","unstructured":"Mundy GR (2002) Metastasis to bone: causes, consequences and therapeutic opportunities. Nat Rev Cancer 2:584\u2013593.","journal-title":"Nat Rev Cancer"},{"key":"555_CR3","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1053\/ctrv.2000.0210","volume":"27","author":"R.E. Coleman","year":"2001","unstructured":"Coleman RE (2001) Metastatic bone disease: clinical features, pathophysiology and treatment strategies. Cancer Treat Rev 27:165\u2013176.","journal-title":"Cancer Treat Rev"},{"key":"555_CR4","first-page":"43","volume-title":"Cancer and the skeleton","author":"G.R. Mundy","year":"2000","unstructured":"Mundy GR, Guise TA (2000) Pathophysiology of bone metastasis. In: Cancer and the skeleton, Third Edition (Rubens RD, Mundy GR, eds), pp 43\u201364. London: Informa Health Care.","edition":"Third Edition"},{"key":"555_CR5","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1007\/s004040000105","volume":"264","author":"U. Ulrich","year":"2001","unstructured":"Ulrich U, Rhiem K, Schmolling J et al (2001) Cross-linked type I collagen C- and N-telopeptides in women with bone metastases from breast cancer. Arch Gynecol Obstet 264:186\u2013190.","journal-title":"Arch Gynecol Obstet"},{"key":"555_CR6","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/S0093-7754(01)90233-7","volume":"28","author":"A. Lipton","year":"2001","unstructured":"Lipton A, Costa L, Ali S et al (2001) Use of markers of bone turnover for monitoring bone metastases and the response to therapy. Semin Oncol 28:54\u201359.","journal-title":"Semin Oncol"},{"key":"555_CR7","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1002\/jbmr.5650060615","volume":"6","author":"P.D. Delmas","year":"1991","unstructured":"Delmas PD, Schlemmer A, Gineyts E et al (1991) Urinary excretion of pyridinoline crosslinks correlates with bone turnover measured on iliac crest biopsy in patients with vertebral osteoporosis. J Bone Miner Res 6:639\u2013644.","journal-title":"J Bone Miner Res"},{"key":"555_CR8","doi-asserted-by":"crossref","first-page":"7829","DOI":"10.1073\/pnas.0601643103","volume":"103","author":"K.L. Kavanagh","year":"2006","unstructured":"Kavanagh KL, Guo K, Dunford JE et al (2006) The molecular mechanism of nitrogen-containing bisphosphonates as antiosteoporosis drugs. Proc Natl Acad Sci U S A 103:7829\u20137834.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"555_CR9","doi-asserted-by":"crossref","first-page":"3721","DOI":"10.1021\/jm020819i","volume":"45","author":"L. Widler","year":"2002","unstructured":"Widler L, Jaeggi KA, Glatt M et al (2002) Highly potent geminal bisphosphonates. From pamidronate disodium (Aredia) to zoledronic acid (Zometa). J Med Chem 45:3721\u20133738.","journal-title":"J Med Chem"},{"key":"555_CR10","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1016\/j.orthres.2005.02.012","volume":"23","author":"J. Yu","year":"2005","unstructured":"Yu J, Chang SS, Suratwala S et al (2005) Zoledronate induces apoptosis in cells from fibro-cellular membrane of unicameral bone cyst (UBC). J Orthop Res 23:1004\u20131012.","journal-title":"J Orthop Res"},{"key":"555_CR11","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1002\/cncr.11128","volume":"97","author":"J.R. Green","year":"2003","unstructured":"Green JR (2003) Antitumor effects of bisphosphonates. Cancer 97:840\u2013847.","journal-title":"Cancer"},{"key":"555_CR12","first-page":"377","volume":"7","author":"L.S. Rosen","year":"2001","unstructured":"Rosen LS, Gordon D, Kaminski M et al (2001) Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial. Cancer J 7:377\u2013387.","journal-title":"Cancer J"},{"key":"555_CR13","doi-asserted-by":"crossref","first-page":"3150","DOI":"10.1200\/JCO.2003.04.105","volume":"21","author":"L.S. Rosen","year":"2003","unstructured":"Rosen LS, Gordon D, Tchekmedyian S et al (2003) Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase III, double-blind, randomized trial\u2014the Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group. J Clin Oncol 21:3150\u20133157.","journal-title":"J Clin Oncol"},{"key":"555_CR14","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1093\/jnci\/94.19.1458","volume":"94","author":"F. Saad","year":"2002","unstructured":"Saad F, Gleason DM, Murray R et al (2002) A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst 94:1458\u20131468.","journal-title":"J Natl Cancer Inst"},{"key":"555_CR15","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/j.ctrv.2008.05.001","volume":"34","author":"R. Coleman","year":"2008","unstructured":"Coleman R, Brown J, Terpos E et al (2008) Bone markers and their prognostic value in metastatic bone disease: clinical evidence and future directions. Cancer Treat Rev 34:629\u2013639.","journal-title":"Cancer Treat Rev"},{"key":"555_CR16","doi-asserted-by":"crossref","first-page":"3314","DOI":"10.1200\/JCO.2005.05.116","volume":"23","author":"N. Kohno","year":"2005","unstructured":"Kohno N, Aogi K, Minami H et al (2005) Zoledronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: a randomized, placebo-controlled trial. J Clin Oncol 23:3314\u20133321.","journal-title":"J Clin Oncol"},{"key":"555_CR17","doi-asserted-by":"crossref","first-page":"346","DOI":"10.3816\/CLM.2007.n.011","volume":"7","author":"A. Lipton","year":"2007","unstructured":"Lipton A, Cook RJ, Coleman RE et al (2007) Clinical utility of biochemical markers of bone metabolism for improving the management of patients with advanced multiple myeloma. Clin Lymphoma Myeloma 7:346\u2013353.","journal-title":"Clin Lymphoma Myeloma"},{"key":"555_CR18","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1038\/sj.bjc.6601437","volume":"89","author":"J.E. Brown","year":"2003","unstructured":"Brown JE, Thomson CS, Ellis SP et al (2003) Bone resorption predicts for skeletal complications in metastatic bone disease. Br J Cancer 89: 2031\u20132037.","journal-title":"Br J Cancer"},{"key":"555_CR19","doi-asserted-by":"crossref","first-page":"2021","DOI":"10.1016\/S0959-8049(98)00277-9","volume":"34","author":"A. Lipton","year":"1998","unstructured":"Lipton A, Demers L, Curley E et al (1998) Markers of bone resorption in patients treated with pamidronate. Eur J Cancer 34:2021\u20132026.","journal-title":"Eur J Cancer"},{"key":"555_CR20","doi-asserted-by":"crossref","first-page":"2353","DOI":"10.1200\/JCO.2002.02.032","volume":"20","author":"H.D. Menssen","year":"2002","unstructured":"Menssen HD, Sakalova A, Fontana A et al (2002) Effects of long-term intravenous ibandronate therapy on skeletal-related events, survival, and bone resorption markers in patients with advanced multiple myeloma. J Clin Oncol 20:2353\u20132359.","journal-title":"J Clin Oncol"},{"key":"555_CR21","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1093\/jnci\/dji002","volume":"97","author":"J.E. Brown","year":"2005","unstructured":"Brown JE, Cook RJ, Major P et al (2005) Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors. J Natl Cancer Inst 97:59\u201369.","journal-title":"J Natl Cancer Inst"},{"key":"555_CR22","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1634\/theoncologist.12-9-1035","volume":"12","author":"A. Lipton","year":"2007","unstructured":"Lipton A, Cook RJ, Major P et al (2007) Zoledronic acid and survival in breast cancer patients with bone metastases and elevated markers of osteoclast activity. Oncologist 12:1035\u20131043.","journal-title":"Oncologist"},{"key":"555_CR23","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1016\/j.juro.2006.06.028","volume":"176","author":"K. Jung","year":"2006","unstructured":"Jung K, Lein M, Ringsdorf M et al (2006) Diagnostic and prognostic validity of serum bone turnover markers in metastatic renal cell carcinoma. J Urol 176:1326\u20131331.","journal-title":"J Urol"},{"key":"555_CR24","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1634\/theoncologist.11-3-227","volume":"11","author":"M. Clemons","year":"2006","unstructured":"Clemons M, Dranitsaris G, Cole D et al (2006) Too much, too little, too late to start again? Assessing the efficacy of bisphosphonates in patients with bone metastases from breast cancer. Oncologist 11:227\u2013233.","journal-title":"Oncologist"},{"key":"555_CR25","unstructured":"UK Clinical Research Network (2009) Cost-effective use of BISphosphonates in metastatic bone disease \u2014 a comparison of bone MARKer directed zoledronic acid therapy to a standard schedule \u2014 The BISMARK Trial. Available at: http:\/\/public.ukcrn.org.uk\/Search\/StudyDetail.aspx?StudyID=1737 (accessed on June, 2009)."},{"key":"555_CR26","unstructured":"NCI (2007) Randomized Study of Bone Marker-Directed Schedule Versus Standard Schedule of Zoledronic Acid in Patients With Advanced Breast Cancer Metastatic to the Bone. Available at: http:\/\/www.cancer.gov\/search\/ViewClinical-Trials.aspx?cdrid=538879&version=HealthProfessional&protocolsearchid=6240196 (accessed on June, 2009)."},{"key":"555_CR27","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1200\/JCO.2000.18.6.1378","volume":"18","author":"B.E. Hillner","year":"2000","unstructured":"Hillner BE, Ingle JN, Berenson JR et al (2000) American Society of Clinical Oncology guideline on the role of bisphosphonates in breast cancer. American Society of Clinical Oncology Bisphosphonates Expert Panel. J Clin Oncol 18:1378\u20131391.","journal-title":"J Clin Oncol"}],"container-title":["Clinical and Translational Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-010-0555-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12094-010-0555-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-010-0555-z","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,2]],"date-time":"2019-06-02T03:50:50Z","timestamp":1559447450000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12094-010-0555-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,8]]},"references-count":27,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2010,8]]}},"alternative-id":["555"],"URL":"https:\/\/doi.org\/10.1007\/s12094-010-0555-z","relation":{},"ISSN":["1699-048X","1699-3055"],"issn-type":[{"value":"1699-048X","type":"print"},{"value":"1699-3055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,8]]}}}